{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-253636","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.572124+00:00","generated_at":"2026-05-17T01:58:43.972148+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"low","headline":"Vor Biopharma reports 48-week Phase 3 data for telitacicept in Sjögren's disease from China","bullets":["Webcast held Oct 28, 2025 to discuss late-breaking 48-week Phase 3 results from China.","Trial evaluates telitacicept in primary Sjögren's disease; no specific efficacy/safety numbers provided in the filing text.","Stock may react to implied data direction, but actual results are not disclosed in this 8-K excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-253636","json":"https://secwatch.observer/filing/0001193125-25-253636.json","markdown":"https://secwatch.observer/filing/0001193125-25-253636.md","text":"https://secwatch.observer/filing/0001193125-25-253636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525253636/0001193125-25-253636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525253636/vor-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:58:43.972148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}